{
    "nctId": "NCT00559845",
    "briefTitle": "A Study of Avastin (Bevacizumab) in Patients With Inflammatory or Locally Advanced Breast Cancer",
    "officialTitle": "Phase II, Open Label, Neoadjuvant Study of Bevacizumab in Patients With Inflammatory or Locally Advanced Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 56,
    "primaryOutcomeMeasure": "Percentage of Participants With Pathological Complete Response Following Principle Investigator Review",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* female participants, \\>=18 years of age;\n* stage III, or inflammatory breast cancer;\n* estrogen receptor/progesterone receptor (ER/PgR) positive or negative and human epidermal growth factor receptor 2 (HER-2) negative;\n* normal left ventricular ejection fraction (LVEF).\n\nExclusion Criteria:\n\n* previous chemotherapy/endocrine therapy;\n* evidence of distant metastatic disease;\n* other primary tumors in last 5 years (except for adequately treated cancer in situ of the cervix, or basal cell skin cancer);\n* chronic daily treatment with \\>325 milligram per day (mg/day) aspirin, or \\>75mg/day clopidogrel.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}